1. PC3 - 154 Phase I/II Study of VAL-083 in Patients with Recurrent Glioblastoma. (18th October 2016) Authors: Shih, K.C.; Patel, M.R.; Butowski, N.; Falchook, G.S.; Kizilbash, S.H.; Bacha, J.A.; Brown, D.M.; Steino, A.; Schwartz, R.; Kanekal, S.; Lopez, L.M.; Burris, H.A. Journal: Canadian journal of neurological sciences Issue: Volume 43(2016)Supplement 4 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor. (October 2020) Authors: Kizilbash, S.H.; El-Khoueiry, A.; Lerner, R.E.; Ma, P.C.; Almubarak, M.; Mody, K.; Burkard, M.E.; Guarino, M.; Jenab-Wolcott, J.; Sankar, N.; Choy, G.; Espiritu, L.; Zhang, X.; Luria, A.; Benedetti, F.; Dees, E.C. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗